In re Application of: LAZARUS, Alan H., et al.

Filed:

10 November 2000

Serial No.:

09/709,249

## **LISTING OF CLAIMS**

This listing of the claims replaces all prior versions and listings of claims in the application:

Claim 1 (currently amended) A method for inhibiting HLA alloimmune response to platelet transfusion, said method comprising the step of presensitizing platelets with at least one monoclonal antibody against HLA <u>Class I</u>, a portion an antigen binding fragment thereof or β2-microglobulin, wherein said platelets if administered to a patient prevent an HLA alloimmune response in patient.

Claim 2 (currently amended) The method of claim 1, wherein said at least one monoclonal antibody is selected from W6/32, L368, or MA2.1, <u>ATCC accession number HB-95, HB-149 and HB-54, respectively.</u>



Claim 3 (currently amended) A method for inhibiting an HLA alloimmune response to platelet transfusion, said method comprising the steps of:

- a) presensitizing platelets with at least one monoclonal antibody against HLA <u>Class I</u>, a portion an antigen binding fragment thereof or β2-microglobulin;
- b) transfusing the presensitized platelets of step a) into a patient, said presensitized platelets inhibiting an HLA alloimmune response in said patient.

Claim 4 (previously amended) The method of claim 3, wherein said HLA alloimmune response is still inhibited after at least two transfusions into said patient.

Claim 5 (currently amended) A method for inhibiting refractoriness to subsequent transfusions in an alloimmunized patient, comprising the steps of:

- a) presensitizing platelets with at least one monoclonal antibody against HLA <u>Class I</u>, a portion an antigen binding fragment thereof or β2-microglobulin; and
- b) transfusing the alloimmunized patient with the presensitized platelets of step a), the presensitized platelets preventing refractoriness to the transfusion.